The report outlines Alnylam's approach to corporate responsibility (CR) and highlights key achievements of the year. The company has made significant progress in expanding its portfolio of RNAi-based treatments, addressing health inequities in local communities, and expanding its efforts in environmental sustainability. The report also includes a materiality assessment and a detailed overview of Alnylam's commitment to diversity, equity, and inclusion.
Issuing Company Alnylam Pharmaceuticals Inc.
Report Type Sustainability Report
Report Language EN
Report Filesize 16.67 MB
No. of Pages 58 pages
Reporting period2021
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB
Materiality Assessmenttrue